BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Everolimus readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Everolimus\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT00819546-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Everolimus: Phase 1 readout est. (NCT00819546)
DESCRIPTION:Everolimus\, phase 1.\nStudy: RAD001 in Combination With PKC412
  in Patients With Relapsed\, Refractory or Poor Prognosis AML or MDS\nEsti
 mated primary completion: December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT00819546
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03114527-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Everolimus: Phase 2 readout est. (NCT03114527)
DESCRIPTION:Everolimus\, phase 2.\nStudy: Phase II Trial of Ribociclib and 
 Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarco
 ma (LMS)\nEstimated primary completion: December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03114527
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07095933-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Everolimus: Phase 1 readout est. (NCT07095933)
DESCRIPTION:Everolimus\, phase 1\, Epilepsy.\nStudy: The Safety and Efficac
 y Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory
  Epilepsy\nEstimated primary completion: 1 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07095933
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04185883-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Everolimus: Phase 1 readout est. (NCT04185883)
DESCRIPTION:Everolimus\, phase 1.\nStudy: Sotorasib Activity in Subjects Wi
 th Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)\nEstima
 ted primary completion: 17 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04185883
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05563220-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Everolimus: Phase 1/2 readout est. (NCT05563220)
DESCRIPTION:Everolimus\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacest
 rant In Various Combination In Participants With Metastatic Breast Cancer\
 nEstimated primary completion: 27 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05563220
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02321501-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Everolimus: Phase 1 readout est. (NCT02321501)
DESCRIPTION:Everolimus\, phase 1.\nStudy: Ceritinib and Everolimus in Treat
 ing Patients With Locally Advanced or Metastatic Solid Tumors or Stage III
 B-IV Non-small Cell Lung Cancer\nEstimated primary completion: 31 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/everolimus#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0232150
 1
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07435584-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Everolimus: Phase 1/2 readout est. (NCT07435584)
DESCRIPTION:Everolimus\, phase 1/2.\nStudy: Everolimus in CDK12-Deficient M
 etastatic Colorectal Cancer (EVER-RECODE)\nEstimated primary completion: 3
 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ever
 olimus#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07435584
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02962414-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Everolimus: Phase 3 readout est. (NCT02962414)
DESCRIPTION:Everolimus\, phase 3\, Epilepsy.\nStudy: Roll-over Study to Col
 lect and Assess Long-term Safety of Everolimus in Patients With TSC and Re
 fractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and 
 Who Are Benefitting From Continued Treatment\nEstimated primary completion
 : 26 February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 verolimus#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT02962414
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05949658-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Everolimus: Phase 1 readout est. (NCT05949658)
DESCRIPTION:Everolimus\, phase 1.\nStudy: Rapalog Pharmacology (RAP PAC) St
 udy\nEstimated primary completion: March 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05949658
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02579044-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Everolimus: Phase 1/2 readout est. (NCT02579044)
DESCRIPTION:Everolimus\, phase 1/2.\nStudy: Phase I/II Trial of Everolimus 
 in Combination With Lonafarnib in Progeria\nEstimated primary completion: 
 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/everolimu
 s#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02
 579044
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02081755-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Everolimus: Phase 4 readout est. (NCT02081755)
DESCRIPTION:Everolimus\, phase 4.\nStudy: Safety and Efficacy of Everolimus
  Treatment in Liver Transplantation for Liver Cancer\nEstimated primary co
 mpletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /everolimus#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT02081755
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07191353-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Everolimus: Phase 2 readout est. (NCT07191353)
DESCRIPTION:Everolimus\, phase 2.\nStudy: Resistance Training and Rapamycin
  to Enhance Bone Formation in Postmenopausal Women\nEstimated primary comp
 letion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /everolimus#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07191353
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01141309-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Everolimus: Phase 2 readout est. (NCT01141309)
DESCRIPTION:Everolimus\, phase 2.\nStudy: Evaluating the Combination of Eve
 rolimus and Sorafenib in the Treatment of Thyroid Cancer\nEstimated primar
 y completion: June 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/everolimus#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT01141309
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05432518-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Everolimus: Phase 1 readout est. (NCT05432518)
DESCRIPTION:Everolimus\, phase 1.\nStudy: Pilot Trial for Treatment of Recu
 rrent Glioblastoma\nEstimated primary completion: 1 July 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/everolimus#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05432518
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07062965-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:Everolimus: Phase 3 readout est. (NCT07062965)
DESCRIPTION:Everolimus\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study to Learn About the Study Medicine Called PF-07248144 in Combin
 ation With Fulvestrant in People With HR-positive\, HER2-negative Advanced
  or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatmen
 t.\nEstimated primary completion: 22 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07062965
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07937553-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Everolimus: Phase 2 readout est. (NCT07937553)
DESCRIPTION:Everolimus\, phase 2\, Renal Cell Carcinoma.\nStudy: Combinatio
 ns With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carc
 inoma.\nEstimated primary completion: 1 August 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07937553
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06382948-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Everolimus: Phase 3 readout est. (NCT06382948)
DESCRIPTION:Everolimus\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Elacestrant + Everolimus in Patients ER+/HER2-\, ESR1mut\, Advanced Br
 east Cancer Progressing to ET and CDK4/6i.\nEstimated primary completion: 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/evero
 limus#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06382948
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06727305-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Everolimus: Phase 1/2 readout est. (NCT06727305)
DESCRIPTION:Everolimus\, phase 1/2.\nStudy: MTOR Inhibitors in Older Adults
 \nEstimated primary completion: 1 September 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06727305
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05012371-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271025
DTEND;VALUE=DATE:20271026
SUMMARY:Everolimus: Phase 2 readout est. (NCT05012371)
DESCRIPTION:Everolimus\, phase 2\, Renal Cell Carcinoma.\nStudy: Lenvatinib
  With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatme
 nt of Metastatic Renal Cell Cancer\nEstimated primary completion: 25 Octob
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/everolimus#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05012
 371
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03955172-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271203
DTEND;VALUE=DATE:20271204
SUMMARY:Everolimus: Phase na readout est. (NCT03955172)
DESCRIPTION:Everolimus\, phase na.\nStudy: Efficiency of Everolimus for the
  Treatment of Kidney Transplanted Patients Presenting a Missing Self-induc
 ed NK-mediated Rejection\nEstimated primary completion: 3 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/everolimus#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03955172
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06730672-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271227
DTEND;VALUE=DATE:20271228
SUMMARY:Everolimus: Phase 2 readout est. (NCT06730672)
DESCRIPTION:Everolimus\, phase 2\, Renal Cell Carcinoma.\nStudy: An Explora
 tory Study on the Failure of Immunotherapy With Vorolanib Combined With Ev
 erolimus\nEstimated primary completion: 27 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06730672
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04485559-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Everolimus: Phase 1 readout est. (NCT04485559)
DESCRIPTION:Everolimus\, phase 1.\nStudy: Trametinib and Everolimus for Tre
 atment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC0
 21)\nEstimated primary completion: 31 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04485559
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05508906-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Everolimus: Phase 1 readout est. (NCT05508906)
DESCRIPTION:Everolimus\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribocicli
 b\, Alpelisib\, Everolimus\, or Atirmociclib in ER+\, HER2- Breast Cancer\
 nEstimated primary completion: 31 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05508906
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05749588-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Everolimus: Phase 2 readout est. (NCT05749588)
DESCRIPTION:Everolimus\, phase 2\, Breast Cancer.\nStudy: FUSCC Refractory 
 TNBC Platform Study (FUTURE2.0)\nEstimated primary completion: 31 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/everolimus#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0574958
 8
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04542733-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Everolimus: Phase na readout est. (NCT04542733)
DESCRIPTION:Everolimus\, phase na.\nStudy: The Efficacy of Everolimus With 
 Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in 
 Treatment of BK Virus Infection in Kidney Transplantation Recipient\nEstim
 ated primary completion: 31 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04542733
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02029001-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Everolimus: Phase 2 readout est. (NCT02029001)
DESCRIPTION:Everolimus\, phase 2.\nStudy: Adapting Treatment to the Tumor M
 olecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecifi
 cTreatment\nEstimated primary completion: January 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT02029001
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07570433-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Everolimus: Phase 4 readout est. (NCT07570433)
DESCRIPTION:Everolimus\, phase 4.\nStudy: HORUS-Cytomegalovirus Open Proof-
 of-concept Exploratory Trial\nEstimated primary completion: January 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/everolimus#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07570433
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01217931-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Everolimus: Phase 2 readout est. (NCT01217931)
DESCRIPTION:Everolimus\, phase 2\, Renal Cell Carcinoma.\nStudy: Sequential
  Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial\nEs
 timated primary completion: 31 January 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT01217931
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05573126-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Everolimus: Phase 1/2 readout est. (NCT05573126)
DESCRIPTION:Everolimus\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination
  in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer\nEst
 imated primary completion: February 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05573126
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03950609-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Everolimus: Phase 2 readout est. (NCT03950609)
DESCRIPTION:Everolimus\, phase 2.\nStudy: Lenvatinib and Everolimus in Trea
 ting Patients With Advanced\, Unresectable Carcinoid Tumors\nEstimated pri
 mary completion: 30 March 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/everolimus#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT03950609
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002177-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Everolimus: Phase 1/2 readout est. (NCT07002177)
DESCRIPTION:Everolimus\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FW
 D1802 in Patients With ER+/HER2- BC\nEstimated primary completion: 1 May 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/everolimus#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07002177
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06280950-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Everolimus: Phase 2 readout est. (NCT06280950)
DESCRIPTION:Everolimus\, phase 2.\nStudy: Expanding Liver Transplant Immuno
 suppression Minimization Via Everolimus\nEstimated primary completion: 30 
 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/everolimus
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT062
 80950
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06658093-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Everolimus: Phase 1 readout est. (NCT06658093)
DESCRIPTION:Everolimus\, phase 1.\nStudy: RESTOR: PK/PD mTORi Inhibition in
  Older Adults\nEstimated primary completion: July 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06658093
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318324-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Everolimus: Phase 1 readout est. (NCT07318324)
DESCRIPTION:Everolimus\, phase 1.\nStudy: Phase Ib Study of Avutometinib\, 
 Defactinib\, and Everolimus in RAS Pathway Mutant Endometrial Cancer\nEsti
 mated primary completion: 1 August 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07318324
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900516-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Everolimus: Phase 2 readout est. (NCT07900516)
DESCRIPTION:Everolimus\, phase 2\, Breast Cancer.\nStudy: A Prospective\, P
 hase II\, Exploratory Study Protocol of a Chemotherapy Sensitivity-based C
 ulmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breas
 t Cancer.\nEstimated primary completion: 1 August 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07900516
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03008408-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Everolimus: Phase 2 readout est. (NCT03008408)
DESCRIPTION:Everolimus\, phase 2.\nStudy: A Phase II\, Two-Arm Study of Eve
 rolimus and Letrozole\, +/- Ribociclib (Lee011) in Patients With Advanced 
 or Recurrent Endometrial Carcinoma\nEstimated primary completion: 31 Augus
 t 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/everolimus#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT030084
 08
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06680921-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Everolimus: Phase 3 readout est. (NCT06680921)
DESCRIPTION:Everolimus\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician
 's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)\nEst
 imated primary completion: 31 August 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06680921
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02397083-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Everolimus: Phase 2 readout est. (NCT02397083)
DESCRIPTION:Everolimus\, phase 2.\nStudy: Levonorgestrel-Releasing Intraute
 rine System With or Without Everolimus in Treating Patients With Atypical 
 Hyperplasia or Stage IA Grade 1 Endometrial Cancer\nEstimated primary comp
 letion: 30 September 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/everolimus#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT02397083
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619950-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Everolimus: Phase 2 readout est. (NCT07619950)
DESCRIPTION:Everolimus\, phase 2.\nStudy: EVERolimus and LenvAtinib Versus 
 Everolimus for Bone Sarcoma\nEstimated primary completion: 30 November 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/everolimus#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07619950
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07634601-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20281218
DTEND;VALUE=DATE:20281219
SUMMARY:Everolimus: Phase 2 readout est. (NCT07634601)
DESCRIPTION:Everolimus\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Elacestrant With Everolimus for the Treatment of Recurrent Advanced or
  Metastatic ER-Positive Endometrial Cancer\nEstimated primary completion: 
 18 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/eve
 rolimus#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07634601
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07165418-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Everolimus: Phase 3 readout est. (NCT07165418)
DESCRIPTION:Everolimus\, phase 3\, Renal Cell Carcinoma.\nStudy: A Comparis
 on of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patie
 nts With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment
  With Immunotherapy Monotherapy or in Combination With TKI\nEstimated prim
 ary completion: 30 December 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/everolimus#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07165418
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07946627-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Everolimus: Phase 2 readout est. (NCT07946627)
DESCRIPTION:Everolimus\, phase 2.\nStudy: Everolimus Post-Bland Hepatic Art
 ery Embolization in Patients With Neuroendocrine Tumors (NETs) With Liver 
 Metastasis\nEstimated primary completion: 31 December 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07946627
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04199026-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Everolimus: Phase na readout est. (NCT04199026)
DESCRIPTION:Everolimus\, phase na.\nStudy: Implantable Microdevice for the 
 Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic o
 r Recurrent Sarcoma\nEstimated primary completion: 31 December 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/everolimus#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04199026
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04803318-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Everolimus: Phase 2 readout est. (NCT04803318)
DESCRIPTION:Everolimus\, phase 2.\nStudy: Trametinib Combined With Everolim
 us and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors\nEstimate
 d primary completion: 1 January 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/everolimus#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04803318
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06994572-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20290416
DTEND;VALUE=DATE:20290417
SUMMARY:Everolimus: Phase 1 readout est. (NCT06994572)
DESCRIPTION:Everolimus\, phase 1.\nStudy: Study of CT-01 as Monotherapy and
  Combination Therapy in Subjects With Intermediate or Advanced Hepatocellu
 lar Carcinoma\nEstimated primary completion: 16 April 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06994572
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04802759-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Everolimus: Phase 1/2 readout est. (NCT04802759)
DESCRIPTION:Everolimus\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Study Evaluating the Efficacy and Safety of Multiple Treatment Com
 binations in Participants With Breast Cancer\nEstimated primary completion
 : 30 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/everol
 imus#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04802759
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739914-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Everolimus: Phase 3 readout est. (NCT07739914)
DESCRIPTION:Everolimus\, phase 3.\nStudy: Everolimus bAsed caLcineurin inhi
 biTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNA
 TION)\nEstimated primary completion: 30 June 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07739914
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05843253-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Everolimus: Phase 2 readout est. (NCT05843253)
DESCRIPTION:Everolimus\, phase 2.\nStudy: Study of Ribociclib and Everolimu
 s in HGG and DIPG or Ribociclib and Temozolomide in DHG\, H3G34-mutant\nEs
 timated primary completion: 31 August 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05843253
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07937605-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Everolimus: Phase 2 readout est. (NCT07937605)
DESCRIPTION:Everolimus\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: KC1086 in Combination With Fulvestrant for HR-Positive\, HER2-Negative
  Advanced Breast Cancer\nEstimated primary completion: November 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/everolimus#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07937605
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06832189-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Everolimus: Phase 1 readout est. (NCT06832189)
DESCRIPTION:Everolimus\, phase 1.\nStudy: EVR and EPO for Liver Transplant 
 Tolerance\nEstimated primary completion: 1 June 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06832189
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972758-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Everolimus: Phase 2 readout est. (NCT06972758)
DESCRIPTION:Everolimus\, phase 2.\nStudy: Adjuvant Everolimus in High-Risk 
 Hepatocellular Carcinoma After Curative Resection (SEVERANCE Trial)\nEstim
 ated primary completion: 1 July 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/everolimus#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06972758
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218575-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Everolimus: Phase 2/3 readout est. (NCT07218575)
DESCRIPTION:Everolimus\, phase 2/3.\nStudy: Double-Blind Trial of Everolimu
 s for Improving Social Abilities in PTEN Germline Mutations\nEstimated pri
 mary completion: September 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/everolimus#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07218575
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05933395-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Everolimus: Phase 2 readout est. (NCT05933395)
DESCRIPTION:Everolimus\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibit
 or\nEstimated primary completion: October 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05933395
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07477548-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Everolimus: Phase 2 readout est. (NCT07477548)
DESCRIPTION:Everolimus\, phase 2.\nStudy: A Study to Evaluate the Efficacy 
 and Safety of Everolimus in Patients With Teratment-refractory Vascular An
 omalies\nEstimated primary completion: 31 October 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07477548
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06942156-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Everolimus: Phase 4 readout est. (NCT06942156)
DESCRIPTION:Everolimus\, phase 4.\nStudy: Optimize Immunosuppressive Therap
 y Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant
  Patients in Korea\nEstimated primary completion: December 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/everolimus#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06942156
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07426484-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20301215
DTEND;VALUE=DATE:20301216
SUMMARY:Everolimus: Phase 4 readout est. (NCT07426484)
DESCRIPTION:Everolimus\, phase 4.\nStudy: Cosibelimab for CSCC in Patients 
 With Kidney Transplant or Hematologic Malignancy\nEstimated primary comple
 tion: 15 December 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/everolimus#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07426484
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02813135-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Everolimus: Phase 1/2 readout est. (NCT02813135)
DESCRIPTION:Everolimus\, phase 1/2.\nStudy: European Proof-of-Concept Thera
 peutic Stratification Trial of Molecular Anomalies in Relapsed or Refracto
 ry Tumors\nEstimated primary completion: February 2031. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT02813135
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340541-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20310602
DTEND;VALUE=DATE:20310603
SUMMARY:Everolimus: Phase 2 readout est. (NCT07340541)
DESCRIPTION:Everolimus\, phase 2\, Breast Cancer.\nStudy: Evolutionary Clin
 ical Trial for Novel Biomarker-Driven Therapies\nEstimated primary complet
 ion: 2 June 2031. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/eve
 rolimus#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07340541
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407517-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20330201
DTEND;VALUE=DATE:20330202
SUMMARY:Everolimus: Phase 3 readout est. (NCT07407517)
DESCRIPTION:Everolimus\, phase 3\, Breast Cancer.\nStudy: Adjuvant Intensif
 ication for LAR\nEstimated primary completion: 1 February 2033. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/everolimus#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07407517
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07865130-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Everolimus: Phase 1 readout est. (NCT07865130)
DESCRIPTION:Everolimus\, phase 1.\nStudy: Study of CDK8 Inhibitor RVU120 in
  Combination With Everolimus in Children With Recurrent or Progressive Gro
 up 3 or 4 Medulloblastoma\nEstimated primary completion: June 2033. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/everolimus#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07865130
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05725200-9023@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20381231
DTEND;VALUE=DATE:20390101
SUMMARY:Everolimus: Phase 2 readout est. (NCT05725200)
DESCRIPTION:Everolimus\, phase 2.\nStudy: Study to Investigate Outcome of I
 ndividualized Treatment in Patients With Metastatic Colorectal Cancer\nEst
 imated primary completion: 31 December 2038. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/everolimus#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05725200
URL:https://assetmemo.bio/drug/everolimus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
